In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [68Ga]Annexin A5 and [18F]FDG PET

Journal of Nuclear Cardiology

Volumn 21, Issue 6, 2014, Pages 1191-1199

  Todica, Andrei ^a   Zacherl, Mathias J ^a   Wang, Hao ^a   Böning, Guido ^a   Jansen, Nathalie L ^a   Wängler, Carmen ^b   Bartenstein, Peter ^a   Kreissl, Michael C ^c   Hacker, Marcus ^d   Brunner, Stefan ^a   Lehner, Sebastian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Annexin; erythropoietin; FDG PET; mice; myocardial infarction; PET; therapy monitoring

Indexed keywords

ERYTHROPOIETIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; LIPOCORTIN 5; PHOSPHATIDYLSERINE; SODIUM CHLORIDE; CARDIOTONIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FOLLOW UP; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; ANIMAL; C57BL MOUSE; DIAGNOSTIC USE; DRUG MONITORING; METABOLISM; MYOCARDIAL INFARCTION; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANIMALS; ANNEXIN A5; CARDIOTONIC AGENTS; DRUG MONITORING; ERYTHROPOIETIN; FLUORODEOXYGLUCOSE F18; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84919819435     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9987-0     Document Type: Article

References (48)

1. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992;72:449-89.
2. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 2013;27:41-53. doi:10.1016/j.blre.2012.12.003.
3. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-31.
4. Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 2004;66:983-9. doi:10.1111/j.1523-1755.2004.00847.x.
5. van der Meer P, van Veldhuisen DJ, Januzzi JL. Erythropoietin in cardiovascular diseases: Exploring new avenues. Clin Sci 2008;114:289-91. doi:10.1042/CS20070392.
6. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004;109:2050-3. doi:10.1161/01.CIR.0000127954.98131.23.
7. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005;19:1323-5. doi:10.1096/fj.04-3545fje.
8. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004;18:1031-3. doi:10.1096/fj.03-1289fje.
9. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6. doi:10.1182/blood-2003-01-0223.
10. Iwai M, Cao G, Yin W, Stetler RA, Liu J, Chen J. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007;38:2795-803. doi:10.1161/STROKEAHA.107.483008.
11. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007;28:2018-27. doi:10.1093/eurheartj/ehm177.
12. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-6. doi:10.1038/86498.
13. Roubille F, Prunier F, Barrère-Lemaire S, Leclercq F, Piot C, Kritikou EA, et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc Drugs Ther 2013;27:315-31. doi:10.1007/s10557-013-6461-1.
14. Brunner S, Winogradow J, Huber BC, Zaruba MM, Fischer R, David R, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 2009;23:351-61. doi:10.1096/fj.08-109462.
15. Stegger L, Hoffmeier AN, Schäfers KP, Hermann S, Schober O, Schäfers MA, et al. Accurate noninvasive measurement of infarct size in mice with high-resolution PET. J Nucl Med 2006;47:1837-44.
16. Stegger L, Heijman E, Schäfers KP, Nicolay K, Schäfers MA, Strijkers GJ. Quantification of left ventricular volumes and ejection fraction in mice using PET, compared with MRI. J Nucl Med 2009;50:132-8. doi:10.2967/jnumed.108.056051.
17. 18F]FDG-PET: Comparison with cardiac MRI and monitoring erythropoietin therapy. EJNMMI Res 2012;2:43. doi:10.1186/2191-219X-2-43.
18. Lehner S, Todica A, Brunner S, Uebleis C, Wang H, Wängler C, et al. Temporal changes in phosphatidylserine expression and glucose metabolism after myocardial infarction: an in vivo imaging study in mice. Mol Imaging 2012;11:461-70.
19. Tyurin VA, Balasubramanian K, Winnica D, Tyurina YY, Vikulina AS, He RR, et al. Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic “eat-me” signals: Cleavage and inhibition of phagocytosis by Lp-PLA2. Cell Death Differ 2014;21:825-35. doi:10.1038/cdd.2014.1.
20. Wollenweber T, Zach C, Rischpler C, Fischer R, Nowak S, Nekolla SG, et al. Myocardial perfusion imaging is feasible for infarct size quantification in mice using a clinical single-photon emission computed tomography system equipped with pinhole collimators. Mol Imaging Biol 2010;12:427-34. doi:10.1007/s11307-009-0281-5.
21. Brunner S, Huber BC, Weinberger T, Vallaster M, Wollenweber T, Gerbitz A, et al. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction. J Cell Mol Med 2012;16:152-9. doi:10.1111/j.1582-4934.2011.01286.x.
22. Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 2006;20:956-8. doi:10.1096/fj.05-4763fje.
23. Wängler C, Wängler B, Lehner S, Elsner A, Todica A, Bartenstein P, et al. A universally applicable 68 Ga-labeling technique for proteins. J Nucl Med 2011;52:586-91. doi:10.2967/jnumed.110.082198.
24. Böning G, Todica A, Vai A, Lehner S, Xiong G, Mille E, et al. Erroneous cardiac ECG-gated PET list-mode trigger events can be retrospectively identified and replaced by an offline reprocessing approach: First results in rodents. Phys Med Biol 2013;58:7937-59. doi:10.1088/0031-9155/58/22/7937.
25. Todica A, Brunner S, Böning G, Lehner S, Nekolla SG, Wildgruber M, et al. [(68)Ga]-albumin-PET in the monitoring of left ventricular function in murine models of Ischemic and dilated cardiomyopathy: Comparison with cardiac MRI. Mol Imaging Biol 2013. doi:10.1007/s11307-013-0618-y.
26. Croteau E, Benard F, Cadorette J, Gauthier ME, Aliaga A, Bentourkia M, et al. Quantitative gated PET for the assessment of left ventricular function in small animals. J Nucl Med 2003;44:1655-61.
27. Slomka PJ, Nishina H, Berman DS, Akincioglu C, Abidov A, Friedman JD, et al. Automated quantification of myocardial perfusion SPECT using simplified normal limits. J Nucl Cardiol 2005;12:66-77.
28. Lehner S, Sussebach C, Todica A, Uebleis C, Brunner S, Bartenstein P, et al. Influence of SPECT attenuation correction on the quantification of hibernating myocardium as derived from combined myocardial perfusion SPECT and (18)F-FDG PET. J Nucl Cardiol 2014. doi:10.1007/s12350-014-9882-8.
29. Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004;45:842-8.
30. Sarda-Mantel L, Hervatin F, Michel JB, Louedec L, Martet G, Rouzet F, et al. Myocardial uptake of 99mTc-annexin-V and 111In-antimyosin-antibodies after ischemia-reperfusion in rats. Eur J Nucl Med Mol Imaging 2008;35:158-65. doi:10.1007/s00259-007-0559-2.
31. De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM. Molecular imaging of cell death. Methods 2009;48:178-87. doi:10.1016/j.ymeth.2009.03.022.
32. Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, et al. Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: Assessment of infarct size with 99mTc-annexin V. J Nucl Med 2008;49:1694-700. doi:10.2967/jnumed.107.050260.
33. Taki J, Higuchi T, Kawashima A, Tait JF, Kinuya S, Muramori A, et al. Detection of cardiomyocyte death in a rat model of ischemia and reperfusion using 99mTc-labeled annexin V. J Nucl Med 2004;45:1536-41.
34. Sanchis-Gomar F, Garcia-Gimenez JL, Pareja-Galeano H, Romagnoli M, Perez-Quilis C, Lippi G. Erythropoietin and the heart: Physiological effects and the therapeutic perspective. Int J Cardiol 2014;171:116-25. doi:10.1016/j.ijcard.2013.12.011.
35. Kagaya Y, Asaumi Y, Wang W, Takeda M, Nakano M, Satoh K, et al. Current perspectives on protective roles of erythropoietin in cardiovascular system: Erythropoietin receptor as a novel therapeutic target. Tohoku J Exp Med 2012;227:83-91.
36. Ueda K, Takano H, Niitsuma Y, Hasegawa H, Uchiyama R, Oka T, et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 2010;120:2016-29. doi:10.1172/JCI39896.
37. Zhang D, Zhang F, Zhang Y, Gao X, Li C, Ma W, et al. Erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction. Cardiology 2007;108:228-36. doi:10.1159/000096803.
38. 18F]2-fluoro-2-deoxy-d-glucose: A new absolute threshold technique. Eur J Nucl Med Mol Imaging 2002;29:203-15.
39. Hernandez-Pampaloni M, Bax JJ, Morita K, Dutka DP, Camici PG. Incidence of stunned, hibernating and scarred myocardium in ischaemic cardiomyopathy. Eur J Nucl Med Mol Imaging 2005;32:314-21. doi:10.1007/s00259-004-1682-y.
40. Mylonas I, Beanlands RS. Radionuclide imaging of viable myocardium: Is it underutilized? Curr Cardiovasc Imaging Rep 2011;4:251-61. doi:10.1007/s12410-011-9074-8.
41. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009;2:1060-8. doi:10.1016/j.jcmg.2009.02.017.
42. Uebleis C, Hellweger S, Laubender RP, Becker A, Sohn HY, Lehner S, et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction. Int J Cardiovasc Imaging 2013. doi:10.1007/s10554-013-0254-2.
43. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-9. doi:10.1016/j.ejheart.2007.10.008.
44. Todica A, Böning G, Lehner S, Weidl E, Cumming P, Wängler C, et al. Positron emission tomography in the assessment of left ventricular function in healthy rats: A comparison of four imaging methods. J Nucl Cardiol 2012. doi:10.1007/s12350-012-9663-1.
45. Hattori N, Bengel FM, Mehilli J, Odaka K, Ishii K, Schwaiger M, et al. Global and regional functional measurements with gated FDG PET in comparison with left ventriculography. Eur J Nucl Med 2001;28:221-9.
46. De Saint-Hubert M, Bauwens M, Mottaghy FM. Molecular imaging of apoptosis for early prediction of therapy efficiency. Curr Pharm Des 2014;20:2319-28.
47. Grunkemeier JM, Tsai WB, Horbett TA. Hemocompatibility of treated polystyrene substrates: Contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J Biomed Mater Res 1998;41:657-70.
48. Zaruba MM, Huber BC, Brunner S, Deindl E, David R, Fischer R, et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res 2008;77:722-31. doi:10.1093/cvr/cvm080.